Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis

Ruihua Wu, Yehuda Shoenfeld, Yaniv Sherer, Madhumita Patnaik, Eiji Matsuura, Boris Gilburd, Takao Koike, James B. Peter

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: The aim of this study was to examine whether intravenous immunoglobulin (IVIg) preparations contain anti-oxLDL and anti-anti-oxLDL antibodies. Background: Oxidized low-density lipoprotein (oxLDL) is one of the major players in atherogenesis. IVIg can reduce atherosclerosis in experimental animal models. Methods: Six commercial IVIg preparations were tested for the presence of anti-oxLDL antibodies by EIA. Inhibition studies were performed with the different IVIg preparations and IgGs purified from a pool of sera from patients with high anti-oxLDL antibody levels. Absorption assays were carried out to evaluate the presence of anti-idiotypes against anti-oxLDL antibodies in IVIg preparations. Results: IVIg preparations tested had various degrees of reactivity towards oxLDL. Absorption experiments suggested that the reactivity was specific because it could be effectively absorbed by oxLDL and not by an irrelevant antigen PPD. The reactivity was smaller than that observed with the IgG from the pool with high anti-oxLDL antibody levels. Inhibition studies with IVIg demonstrated 20-45% inhibition of anti-oxLDL binding to oxLDL, compared to 76% inhibition by the pool with high anti-oxLDL levels. To investigate the presence of anti-idiotypes against anti-oxLDL antibodies within IVIg, F(ab′)2 fragments of IVIg IgG were used to absorb IgG F(ab′)2 fragments from the pool of sera with high anti-oxLDL levels. The decreased binding to oxLDL of the absorbed supernatants shows that IgG F(ab′)2 fragments of the IVIg preparations had high inhibitory capacities ranging from 65 to 90%. Conclusions: IVIg preparations contain both anti-oxLDL and anti-anti-oxLDL activity. This finding may explain the immunomodulating effect of IVIg in atherosclerosis.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalAutoimmunity
Volume36
Issue number2
DOIs
Publication statusPublished - Mar 2003

Fingerprint

Immunomodulation
Intravenous Immunoglobulins
Atherosclerosis
Antibodies
Immunoglobulin G
oxidized low density lipoprotein
low density lipoprotein inhibitor
Tuberculin
Serum

Keywords

  • Anti-idiotype
  • Atherosclerosis
  • Idiotype
  • Intravenous immunoglobulin
  • Oxidized low-density lipoprotein

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis. / Wu, Ruihua; Shoenfeld, Yehuda; Sherer, Yaniv; Patnaik, Madhumita; Matsuura, Eiji; Gilburd, Boris; Koike, Takao; Peter, James B.

In: Autoimmunity, Vol. 36, No. 2, 03.2003, p. 91-97.

Research output: Contribution to journalArticle

Wu, Ruihua ; Shoenfeld, Yehuda ; Sherer, Yaniv ; Patnaik, Madhumita ; Matsuura, Eiji ; Gilburd, Boris ; Koike, Takao ; Peter, James B. / Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis. In: Autoimmunity. 2003 ; Vol. 36, No. 2. pp. 91-97.
@article{7177b1f86e234ac0ad383e237c5f1008,
title = "Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis",
abstract = "Objective: The aim of this study was to examine whether intravenous immunoglobulin (IVIg) preparations contain anti-oxLDL and anti-anti-oxLDL antibodies. Background: Oxidized low-density lipoprotein (oxLDL) is one of the major players in atherogenesis. IVIg can reduce atherosclerosis in experimental animal models. Methods: Six commercial IVIg preparations were tested for the presence of anti-oxLDL antibodies by EIA. Inhibition studies were performed with the different IVIg preparations and IgGs purified from a pool of sera from patients with high anti-oxLDL antibody levels. Absorption assays were carried out to evaluate the presence of anti-idiotypes against anti-oxLDL antibodies in IVIg preparations. Results: IVIg preparations tested had various degrees of reactivity towards oxLDL. Absorption experiments suggested that the reactivity was specific because it could be effectively absorbed by oxLDL and not by an irrelevant antigen PPD. The reactivity was smaller than that observed with the IgG from the pool with high anti-oxLDL antibody levels. Inhibition studies with IVIg demonstrated 20-45{\%} inhibition of anti-oxLDL binding to oxLDL, compared to 76{\%} inhibition by the pool with high anti-oxLDL levels. To investigate the presence of anti-idiotypes against anti-oxLDL antibodies within IVIg, F(ab′)2 fragments of IVIg IgG were used to absorb IgG F(ab′)2 fragments from the pool of sera with high anti-oxLDL levels. The decreased binding to oxLDL of the absorbed supernatants shows that IgG F(ab′)2 fragments of the IVIg preparations had high inhibitory capacities ranging from 65 to 90{\%}. Conclusions: IVIg preparations contain both anti-oxLDL and anti-anti-oxLDL activity. This finding may explain the immunomodulating effect of IVIg in atherosclerosis.",
keywords = "Anti-idiotype, Atherosclerosis, Idiotype, Intravenous immunoglobulin, Oxidized low-density lipoprotein",
author = "Ruihua Wu and Yehuda Shoenfeld and Yaniv Sherer and Madhumita Patnaik and Eiji Matsuura and Boris Gilburd and Takao Koike and Peter, {James B.}",
year = "2003",
month = "3",
doi = "10.1080/0891693031000080228",
language = "English",
volume = "36",
pages = "91--97",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations - Possible immunomodulation of atherosclerosis

AU - Wu, Ruihua

AU - Shoenfeld, Yehuda

AU - Sherer, Yaniv

AU - Patnaik, Madhumita

AU - Matsuura, Eiji

AU - Gilburd, Boris

AU - Koike, Takao

AU - Peter, James B.

PY - 2003/3

Y1 - 2003/3

N2 - Objective: The aim of this study was to examine whether intravenous immunoglobulin (IVIg) preparations contain anti-oxLDL and anti-anti-oxLDL antibodies. Background: Oxidized low-density lipoprotein (oxLDL) is one of the major players in atherogenesis. IVIg can reduce atherosclerosis in experimental animal models. Methods: Six commercial IVIg preparations were tested for the presence of anti-oxLDL antibodies by EIA. Inhibition studies were performed with the different IVIg preparations and IgGs purified from a pool of sera from patients with high anti-oxLDL antibody levels. Absorption assays were carried out to evaluate the presence of anti-idiotypes against anti-oxLDL antibodies in IVIg preparations. Results: IVIg preparations tested had various degrees of reactivity towards oxLDL. Absorption experiments suggested that the reactivity was specific because it could be effectively absorbed by oxLDL and not by an irrelevant antigen PPD. The reactivity was smaller than that observed with the IgG from the pool with high anti-oxLDL antibody levels. Inhibition studies with IVIg demonstrated 20-45% inhibition of anti-oxLDL binding to oxLDL, compared to 76% inhibition by the pool with high anti-oxLDL levels. To investigate the presence of anti-idiotypes against anti-oxLDL antibodies within IVIg, F(ab′)2 fragments of IVIg IgG were used to absorb IgG F(ab′)2 fragments from the pool of sera with high anti-oxLDL levels. The decreased binding to oxLDL of the absorbed supernatants shows that IgG F(ab′)2 fragments of the IVIg preparations had high inhibitory capacities ranging from 65 to 90%. Conclusions: IVIg preparations contain both anti-oxLDL and anti-anti-oxLDL activity. This finding may explain the immunomodulating effect of IVIg in atherosclerosis.

AB - Objective: The aim of this study was to examine whether intravenous immunoglobulin (IVIg) preparations contain anti-oxLDL and anti-anti-oxLDL antibodies. Background: Oxidized low-density lipoprotein (oxLDL) is one of the major players in atherogenesis. IVIg can reduce atherosclerosis in experimental animal models. Methods: Six commercial IVIg preparations were tested for the presence of anti-oxLDL antibodies by EIA. Inhibition studies were performed with the different IVIg preparations and IgGs purified from a pool of sera from patients with high anti-oxLDL antibody levels. Absorption assays were carried out to evaluate the presence of anti-idiotypes against anti-oxLDL antibodies in IVIg preparations. Results: IVIg preparations tested had various degrees of reactivity towards oxLDL. Absorption experiments suggested that the reactivity was specific because it could be effectively absorbed by oxLDL and not by an irrelevant antigen PPD. The reactivity was smaller than that observed with the IgG from the pool with high anti-oxLDL antibody levels. Inhibition studies with IVIg demonstrated 20-45% inhibition of anti-oxLDL binding to oxLDL, compared to 76% inhibition by the pool with high anti-oxLDL levels. To investigate the presence of anti-idiotypes against anti-oxLDL antibodies within IVIg, F(ab′)2 fragments of IVIg IgG were used to absorb IgG F(ab′)2 fragments from the pool of sera with high anti-oxLDL levels. The decreased binding to oxLDL of the absorbed supernatants shows that IgG F(ab′)2 fragments of the IVIg preparations had high inhibitory capacities ranging from 65 to 90%. Conclusions: IVIg preparations contain both anti-oxLDL and anti-anti-oxLDL activity. This finding may explain the immunomodulating effect of IVIg in atherosclerosis.

KW - Anti-idiotype

KW - Atherosclerosis

KW - Idiotype

KW - Intravenous immunoglobulin

KW - Oxidized low-density lipoprotein

UR - http://www.scopus.com/inward/record.url?scp=0344089215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344089215&partnerID=8YFLogxK

U2 - 10.1080/0891693031000080228

DO - 10.1080/0891693031000080228

M3 - Article

VL - 36

SP - 91

EP - 97

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

IS - 2

ER -